Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Immunol. 2002 May;2(5):364-71. doi: 10.1038/nri802.

Development of anti-TNF therapy for rheumatoid arthritis.

Author information

1
Kennedy Institute, Rheumatology Division, Faculty of Medicine, Imperial College School of Medicine, London, UK. m.feldmann@ic.ac.uk

Abstract

The aetiology of systemic, autoimmune, chronic inflammatory diseases--such as rheumatoid arthritis--is not known, and their pathogenesis is complex and multifactorial. However, progress in the characterization of intercellular mediators--proteins that are now known as cytokines--has led to the realization that one cytokine, tumour-necrosis factor (TNF; previously known as TNF-alpha), has an important role in the pathogenesis of rheumatoid arthritis. This discovery heralded a new era of targeted and highly effective therapeutics for rheumatoid arthritis and, subsequently, other chronic inflammatory diseases.

PMID:
12033742
DOI:
10.1038/nri802
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center